Mechanisms Underlying the Greater Efficacy of Robot-Assisted Gait Rehabilitation Versus Conventional Therapy Combined With Botulinum Toxin Injection of the Triceps Surae in Individuals With Chronic Post-Stroke Impairments (NEUROBOST)

November 16, 2026 updated by: COTINAT Maeva, Aix Marseille Université

Stroke is a leading cause of long-term disability in adults. Many people who have had a stroke continue to experience difficulty walking because of muscle weakness and spasticity, which can limit their mobility and quality of life.

Botulinum toxin injections are commonly used to reduce spasticity in specific muscles, such as the calf muscles. Rehabilitation is then used to improve walking ability. Robot-assisted gait rehabilitation allows patients to practice walking intensively and repeatedly, with assistance adjusted to their needs. Previous research from our team has shown that robot-assisted gait rehabilitation may improve walking ability more than conventional physical therapy when combined with botulinum toxin injections.

The purpose of this study is to better understand why robot-assisted gait rehabilitation may be more effective than conventional gait rehabilitation after botulinum toxin treatment in people with chronic stroke. The study will examine changes in walking patterns, muscle activity, and brain activity during and after rehabilitation. Brain activity and brain connections will be assessed using non-invasive methods, including functional near-infrared spectroscopy (fNIRS), electroencephalography (EEG), and magnetic resonance imaging (MRI).

The study may help identify how the brain and body adapt to rehabilitation and may contribute to developing more personalized rehabilitation programs for people living with long-term effects of stroke.

Study Overview

Detailed Description

Stroke is a major cause of acquired motor disability in adults. In the chronic phase after stroke, persistent motor impairment is frequently associated with spastic paresis, altered motor control, and maladaptive or compensatory reorganization of the central nervous system. Spasticity may contribute substantially to gait impairment and reduced mobility, thereby affecting functional independence and quality of life.

Botulinum toxin type A (BoNT-A) is an established treatment for focal spasticity after stroke. Intramuscular injection into the triceps surae reduces excessive muscle activity through its action at the neuromuscular junction and can temporarily improve the mechanical conditions for walking. In addition to these peripheral effects, BoNT-A may also indirectly influence central motor networks by modifying proprioceptive and afferent sensory input, potentially promoting cortical reorganization.

Following BoNT-A injection, intensive rehabilitation is required to optimize functional recovery. Robot-assisted gait rehabilitation provides a means of delivering intensive, repetitive, task-specific gait practice, with partial body-weight support and adjustable motor assistance. This approach may allow patients to perform a greater number of gait cycles and to train at higher walking speeds than conventional gait therapy. Previous studies have suggested that robot-assisted gait rehabilitation may improve gait performance, propulsion, gait symmetry, and motor coordination. In a previous study conducted by our research team, robot-assisted gait rehabilitation performed after BoNT-A injection into the triceps surae resulted in a significantly greater improvement in 6-minute walk distance than conventional gait rehabilitation.

The present study aims to investigate the neurophysiological and biomechanical mechanisms underlying the potentially greater benefit of robot-assisted gait rehabilitation compared with conventional gait rehabilitation following BoNT-A treatment in individuals with chronic stroke.

The study will characterize changes in gait performance and gait biomechanics, including spatiotemporal parameters, lower-limb joint kinematics, ground reaction forces, propulsion, and muscle activation patterns. These measurements will be used to determine whether specific changes in gait mechanics and neuromuscular coordination are associated with the greater improvement observed following robot-assisted rehabilitation.

In parallel, the study will investigate changes in brain activity and functional organization associated with rehabilitation. Functional near-infrared spectroscopy (fNIRS) will be used to assess cortical activation during walking. Electroencephalography (EEG) will be used to characterize cortical electrical activity and functional connectivity, with particular attention to changes in frontoparietal and motor networks. Resting-state functional magnetic resonance imaging (fMRI) and diffusion MRI will be used to assess functional and structural brain connectivity, respectively, as well as lesion characteristics and the organization of motor networks.

A particular focus will be placed on changes in the lateralization and organization of motor cortical activity following rehabilitation. The study will test the hypothesis that robot-assisted gait rehabilitation induces more effective neuroplastic adaptations than conventional gait rehabilitation after BoNT-A treatment. These adaptations are expected to involve a shift toward more efficient recruitment and functional organization of ipsilesional motor regions, together with changes in interhemispheric and network-level connectivity.

The study will also investigate whether central effects of BoNT-A can be detected through changes in cortical activity, including modifications of ipsilesional posterior parietal cortex activity previously reported after BoNT-A treatment.

By combining complementary neurophysiological, neuroimaging, biomechanical, and clinical measures, the study aims to identify mechanisms associated with improved walking recovery after BoNT-A combined with robot-assisted gait rehabilitation. An additional objective is to identify quantitative biomarkers that may help predict which individuals are most likely to benefit from this rehabilitation strategy and, ultimately, contribute to more individualized rehabilitation approaches for people with chronic post-stroke motor impairment.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults with hemiparesis.
  • Affiliated with a national or public health insurance system.
  • Able and willing to provide written informed consent after receiving information about the purpose, procedures, and potential risks of the study.
  • At least 6 months after a unilateral stroke.
  • Presence of triceps surae spasticity causing impaired gait and treatment with botulinum toxin type A (BoNT-A) as part of routine care, with a stable dose for at least 2 treatment cycles.
  • Able to walk for 6 minutes; walking speed <0.8 m/s on the 10-Meter Walk Test.

Exclusion Criteria:

  • Cognitive impairment preventing the participant from providing informed consent.
  • Triceps surae spasticity >3/5 on the Modified Ashworth Scale.
  • Any contraindication to physical exercise, robot-assisted gait rehabilitation using the Lokomat, or MRI.
  • Claustrophobia or fear of confined spaces.
  • Individuals deprived of liberty by judicial or administrative decision, or under legal guardianship.
  • Inability to complete all study procedures.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study period.
  • Concurrent participation in another research study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Robot-Assisted Gait Rehabilitation

Participants receive robot-assisted gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of intensive, repetitive gait training using a robotic device, with adjustable assistance and body-weight support as appropriate.

Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.

Other Names:
  • EEG
  • fNIRS

The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.

Other Names:
  • MRI
  • Magnetic resonance imaging

Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.

Other Names:
  • 6MWT

Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Other Names:
  • MRC Scale

Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.

Other Names:
  • BBS
Active Comparator: Conventional Gait Rehabilitation

Participants receive conventional gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of therapist-guided gait training and conventional physical therapy according to standard clinical practice.

Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.

Other Names:
  • EEG
  • fNIRS

The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.

Other Names:
  • MRI
  • Magnetic resonance imaging

Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.

Other Names:
  • 6MWT

Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Other Names:
  • MRC Scale

Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.

Other Names:
  • BBS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in the Lateralization Index of Nodal Degree in the Paracentral Lobules
Time Frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

The primary outcome measure is the between-group difference in the organization of motor functional brain networks following botulinum toxin type A (BoNT-A) treatment of spasticity in the triceps surae, comparing robot-assisted gait rehabilitation with conventional gait rehabilitation.

At rest, functional brain network organization will be assessed using resting-state functional magnetic resonance imaging (rs-fMRI). The primary resting-state parameter will be the lateralization index (Lik) of nodal degree (k) in the paracentral lobules ipsilateral and contralateral to the stroke lesion. The Lik will be used to quantify the relative distribution of nodal connectivity between the two hemispheres.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Difference in the Lateralization Index of Activation in the Sensorimotor Cortex Derived From fNIRS Data
Time Frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

The lateralization index of cortical activation in the sensorimotor cortex will be calculated from functional near-infrared spectroscopy (fNIRS) data collected during walking. The outcome measure will assess the difference in the lateralization of sensorimotor cortical activation between robot-assisted gait rehabilitation and conventional gait rehabilitation following botulinum toxin type A treatment of spasticity in the triceps surae. Higher or lower lateralization index values will indicate a relative predominance of activation in one cerebral hemisphere.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lateralization of Brain Activation in Locomotor-Related Cortical Areas During Walking
Time Frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

The lateralization of brain activation in cortical areas involved in locomotion, including the prefrontal cortex (PFC), premotor cortex (PMC), and supplementary motor area (SMA), will be assessed during walking using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Differences in the lateralization of cortical activation between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups will be evaluated following botulinum toxin type A treatment of spasticity in the triceps surae.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Change in Resting-State Activity of the Ipsilesional Posterior Parietal Cortex
Time Frame: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in activity of the posterior parietal cortex ipsilateral to the stroke lesion. The change in resting-state activity will be compared between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups following botulinum toxin type A treatment of spasticity in the triceps surae.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

June 1, 2029

Study Completion (Estimated)

June 1, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe